Shanghai Cancer Institute

Other

Carsgen Therapeutics Limited

Shanghai Yijie Biotechnology Co., Ltd

Shengli Yang

Jianren Gu

Zonghai Li

Bizhi Shi

Min Zhou

Gang Huang

Huamao Wang

Hua Jiang

Tao Chen

Haitao Zhang

Hai Feng Wang

Hongyang Wang

Yanjun Yu

Haiyan You

Shile Sheng

Wenxin Qin

Huiping Gao

Bingqian Shen

Kesang Li

Xiaorong Pan

A nucleic acid encoding a chimeric antigen receptor expressed at surface of a T lymphocyte, said chimeric antigen receptor comprises, connected in the order of, an extracellular binding domain, a transmembrane region, and an intracellular signaling domain, wherein the extracellular binding domain comprises a single chain antibody, scFv(GPC3), which specifically recognizes the C-terminal epitope of GPC3. A genetically modified T lymphocyte having a chimeric antigen receptor expressed at surface thereof, and the chimeric antigen receptor is expressed by the nucleic acid described above.

Chimeric antigen receptors targeting GPC3 and uses thereof

The present invention provides an epidermal growth factor receptor variant-de4 EGFR protein. The variant lacks the fourth exon of the epidermal growth factor receptor, and promotes tumor cell invasion/metastasis. The present invention also provides an encoding gene for the variant and a method of producing the variant by means of recombination technology.

Human epidermal growth factor receptor variant lacking an exon

Provided are a novel Epidermal growth factor receptor variant-EGFRvA protein, a polynucleotide encoding the EGFRvA protein and a method of preparing the EGFRvA protein via recombination technology. Also provided is a uses of the polynucleotide encoding the EGFRvA protein. The EGFRvA protein has a function of promoting tumor cell invasion or promoting tumor cell migration.

Epidermal growth factor receptor variants and pharmaceutical compositions thereof

Use of DKK-1 protein or the nucleic acid sequence in preparation of cancer diagnostic agents or kits, method to detect liver cancer with the monoclonal antibody thereof, the kit comprising anti-DKK-1 antibody or protein specific nucleic acid probes, together with a label, and method to detecting specific DKK-1 protein expression are disclosed.

Use of DKK-1 protein in the cancer diagnosis

The invention provides specific binding proteins and the uses thereof. Particularly, the present invention provides a monoclonal antibody which can effectively bind to epidermal growth factor receptor variant type III (EGFRvIII) or can partially bind to the epidermal growth factor receptor (EGFR) over-expressed in cells, but not bind to EGFR normally-expressed in cells. Furthermore, the present invention said antibody has obvious therapeutic effect on a tumor cell line expressing the EGFRvIII. The invention also provides a method for preparing said monoclonal antibody and a pharmaceutical composition comprising said monoclonal antibody.

Anti-EFGRv3 monoclonal antibody

The present invention discloses a method for preparing alginate nanocapsules, including the steps of: (a) forming a water-in-oil emulsion including an alginate in water, an oil, and at least one nonionic surfactant; and (b) separating the aqueous phase and oil phase to obtain the semisolid form alginate nanocapsules; and (c) by ionically crosslinking the alginate with calcium ions to obtain a colloidal form of calcium alginate nanocapsules for drug delivery.

Composition and method for preparing alginate nanocapsules

The present invention relates to a novel human longevity assurance protein, the polynucleotide encoding the polypeptide and a process for producing the polypeptide by recombinant methods. The present invention also relates to a method of applying the polypeptide for the treatment of various kinds of disease, such as cancer. Further, the present invention relates to the antagonist of the polypeptide and therapeutic use of the same. In addition, the present invention includes the use of the polynucleotide encoding the human longevity assurance protein.

Human longevity assurance protein, its coding sequence and their use

Growing community of inventors

Shanghai, China

Shengli Yang